The management of stroke in antiphospholipid syndrome

Current Rheumatology Reports

Volumn 14, Issue 1, 2012, Pages 99-106

  Panichpisal, Kessarin ^a   Rozner, Eduard ^a   Levine, Steven R ^a  

^a Downstate Health Sciences University   (United States)

Author keywords

Anticardiolipin; Antiphospholipid syndrome; Ischemic stroke; Lupus anticoagulant; Management; Stroke; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CARDIOLIPIN ANTIBODY; DABIGATRAN; FLUINDOSTATIN; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; RITUXIMAB; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

AGE; ALTERNATIVE MEDICINE; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; IMMUNOMODULATION; LUNG EMBOLISM; MONOTHERAPY; PLASMAPHERESIS; PRACTICE GUIDELINE; RECURRENT DISEASE; RECURRENT THROMBOSIS; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; STROKE; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VEIN THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; HUMANS; STROKE;

EID: 84857046132     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0223-5     Document Type: Article

References (45)

1. Lim W: Antiphospholipid antibody syndrome. Hematology Am Soc Hematol Educ Program. 2009, 233-9.
2. CE Rodrigues JF Carvalho Y Shoenfeld 2010 Neurological manifestations of antiphospholipid syndrome Eur J Clin Invest. 40 350 9 20192975 10.1111/j.1365-2362.2010.02263.x
3. V Janardhan PA Wolf CS Kase, et al. 2004 Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: The Framingham Cohort and Offspring Study Stroke 35 736 41 14764933 10.1161/01.STR.0000117575.48205.2D (Pubitemid 38280851)
4. E Ahmed B Stegmayr J Trifunovic, et al. 2000 Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Västerbotten cohort project Stroke 31 1289 93 10835446 10.1161/01.STR.31.6.1289 1:STN:280:DC%2BD3c3pslSrsw%3D%3D (Pubitemid 30351247)
5. RL Brey RD Abbott JD Curb, et al. 2001 Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program Stroke 32 1701 6 11486093 10.1161/01.STR.32.8.1701 1:CAS:528:DC%2BD3MXms1ehtLo%3D (Pubitemid 32772193)
6. KE Sletnes P Smith M Abdelnoor, et al. 1992 Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke Lancet 339 451 3 1346819 10.1016/0140-6736(92)91057-F 1:STN:280:DyaK387lslKqug%3D%3D
7. SR Levine RL Brey BC Tilley, et al. 2004 Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke JAMA 291 576 84 14762036 10.1001/jama.291.22.2702 1:CAS:528:DC%2BD2cXhtVylurc%3D (Pubitemid 38500311)
8. KS Ginsburg MH Liang L Newcomer, et al. 1992 Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis Ann Intern Med 117 997 1002 1443986 1:STN:280:DyaK3s%2Fntlelsg%3D%3D
9. G Finazzi V Brancaccio M Moia, et al. 1996 Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a 4-year prospective study from the Italian Registry Am J Med 100 530 6 8644765 10.1016/S0002-9343(96)00060-5 1:STN:280:DyaK283ktVWgtg%3D%3D (Pubitemid 26170477)
10. SR Levine L Salowich-Palm KL Sawaya, et al. 1997 IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study Stroke 28 1660 5 9303006 10.1161/01.STR.28.9.1660 1:STN:280:DyaK2svkvVKrsw%3D%3D (Pubitemid 27391430)
11. RL Brey J Chapman SR Levine, et al. 2003 Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002 Lupus 12 508 13 12892389 10.1191/0961203303lu390oa 1:STN:280:DC%2BD3szlvFCntg%3D%3D (Pubitemid 36890141)
12. G Ruiz-Irastorza 2007 The treatment of antiphospholipid syndrome: a harmonic contrast Best Pract Res Clin Rheumatol. 21 1079 92 18068863 10.1016/j.berh.2007.10.003 1:CAS:528:DC%2BD2sXhsVSrsrnO (Pubitemid 350194042)
13. RL Brey CL Stallworth DL McGlasson, et al. 2002 Antiphospholipid antibodies and stroke in young women Stroke 33 2396 401 12364727 10.1161/01.STR.0000031927.25510.D1 1:CAS:528:DC%2BD38Xntlamsr8%3D
14. RT Urbanus B Siegerink M Roest, et al. 2009 Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study Lancet Neurol 8 998 1005 19783216 10.1016/S1474-4422(09)70239-X 1:CAS:528:DC%2BD1MXhsVertbbL This large case-control study showed that LA is a major risk factor for arterial thrombosis in women, and the presence of other risk factor increases the risk even further
15. KL Furie SE Kasner RJ Adams, et al. 2011 Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 42 227 76 20966421 10.1161/STR.0b013e3181f7d043
16. RL Brey E Muscal J Chapman 2011 Antiphospholipid antibodies and the brain: a consensus report Lupus 20 153 7 21303831 10.1177/0961203310396748 1:STN:280:DC%2BC3M7nvVWqsg%3D%3D
17. JI Tuthill MA Khamashta 2009 Management of antiphospholipid syndrome J Autoimmune 33 92 8 10.1016/j.jaut.2009.05.002 1:CAS:528:DC%2BD1MXpvF2mt7Y%3D
18. LM de Lau FW Leebeek MP de Maat, et al. 2010 A review of hereditary and acquired coagulation disorders in the aetiology of ischaemic stroke Int J Stroke 5 385 94 20854623 10.1111/j.1747-4949.2010.00468.x
19. G Ruiz-Irastorza MJ Cuadrado I Ruiz-Arruza, et al. 2011 Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies Lupus 20 206 18 21303837 10.1177/0961203310395803 1:STN:280:DC%2BC3M7nvVWqtw%3D%3D This is the latest consensus document following a systematic and critical review of the literature on primary and secondary thromboprophylaxis in individuals with aPLs
20. Ortel TL: Thrombosis and the antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 2005; 462-8.
21. D Erdogan MT Goren R Diz-Kucukkaya M Inanc 2005 Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study Stroke 36 592 6 15677581 10.1161/01.STR.0000154858.27353.df (Pubitemid 40344161)
22. I Koniari SN Siminelakis NG Baikoussis, et al. 2010 Antiphospholipid syndrome; its implication in cardiovascular diseases: a review J Cardiothorac Surg 5 101 21047408 10.1186/1749-8090-5-101 This is a good review of cardiac disease in APS
23. M Turiel P Sarzi-Puttini R Peretti, et al. 2005 Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study Stroke 36 1490 4 15947270 10.1161/01.STR.0000170645.40562.09 (Pubitemid 40967518)
24. •• Caplan LR. Overview of the evaluation of stroke In: UpToDate, Kasner SE(Ed), UpToDate, Waltham, MA, 2011. This is an excellent topic review for initial stroke evaluation.
25. W Lim MA Crowther JW Eikelboom 2006 Management of antiphospholipid antibody syndrome: a systematic review JAMA 295 1050 7 16507806 10.1001/jama.295.9.1050 1:CAS:528:DC%2BD28XhvFymsrk%3D
26. MA Crowther JS Ginsberg J Julian, et al. 2003 A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome N Engl J Med 349 1133 8 13679527 10.1056/NEJMoa035241 1:CAS:528:DC%2BD3sXnsV2jtb4%3D (Pubitemid 37122325)
27. E Muscal RL Brey 2010 Antiphospholipid syndrome and the brain in pediatric and adult patients Lupus 19 406 11 20353978 10.1177/0961203309360808 1:STN:280:DC%2BC3c3isVGgsg%3D%3D
28. H Okuma Y Kitagawa T Yasuda, et al. 2009 Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome Int J Med Sci 7 15 8 20046230
29. G Ruiz-Irastorza MA Khamashta 2007 The treatment of antiphospholipid syndrome: a harmonic contrast Best Pract Res Clin Rheumatol 21 1079 92 18068863 10.1016/j.berh.2007.10.003 1:CAS:528:DC%2BD2sXhsVSrsrnO (Pubitemid 350194042)
30. G Hughes 2009 Rituximab in lupus and beyond: the state of the art Lupus 18 639 44 19433465 10.1177/0961203309105337 1:STN:280:DC%2BD1MzjslGquw%3D%3D
31. RL Bick J Rice 1999 Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety-a preliminary report Clin Appl Thromb Hemost 5 S67 71 10726039 10.1177/107602969900500112 1:CAS:528:DyaK1MXnvVWqu7s%3D
32. • Vargas-Hitos JA, Ateka-Barrutia O, Sangle S, Khamashta MA: Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome. Ann Rheum Dis, 2011 May 30. [Epub ahead of print]. This is the latest study of LMWH in APS.
33. SJ Connolly MD Ezekowitz S Yusuf, et al. 2009 Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139 51 19717844 10.1056/NEJMoa0905561 1:CAS:528:DC%2BD1MXhtFOjsLnN
34. D Hurley 2011 FDA approval sought for rivaroxaban to prevent stroke in atrial fibrillation Neurology Today 11 22 3
35. I Ahrens GY Lip K Peter 2011 What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost 105 574 8 21225102 10.1160/TH10-12-0808 1:CAS:528:DC%2BC3MXmt1WktLk%3D This is a good summary of new oral anticoagulants
36. C Laino 2011 Apixaban outperforms aspirin in stroke prevention Neurology Today 11 1 12 4
37. SJ Connolly J Eikelboom C Joyner, et al. 2011 Apixaban in patients with atrial fibrillation N Engl J Med 364 806 17 21309657 10.1056/NEJMoa1007432 1:CAS:528:DC%2BC3MXivV2kurc%3D
38. H Cohen SJ Machin 2010 Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants Lupus 19 486 91 20353992 10.1177/0961203310361355 1:CAS:528:DC%2BC3cXmtVygs78%3D
39. SS Pierangeli D Erkan 2010 Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus 19 475 85 20353991 10.1177/ 0961203310361489 1:CAS:528:DC%2BC3cXmtVygs74%3D
40. AA Mehdi I Uthman M Khamashta 2010 Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future Eur J Clin Invest 40 451 64 20345380 10.1111/j.1365-2362.2010.02281.x 1:CAS:528: DC%2BC3cXms1yitLs%3D This is a good review of novel therapies for APS
41. D Kumar RA Roubey 2010 Use of rituximab in the antiphospholipid syndrome Curr Rheumatol Rep. 12 40 4 20425532 10.1007/s11926-009-0074-5 1:CAS:528:DC%2BC3cXht1Cjsb3O
42. P Kahn M Ramanujam R Bethunaickan, et al. 2008 Prevention of murine antiphospholipid syndrome by BAFF blockade Arthritis Rheum 58 2824 18759321 10.1002/art.23764
43. RL Brey 2004 New treatment option for the antiphospholipid antibody syndrome? More pleiotropic effects of the statin drugs J Thromb Haemost 2 1556 7 15333030 10.1111/j.1538-7836.2004.00904.x 1:CAS:528:DC%2BD2cXosF2rtLs%3D (Pubitemid 40186170)
44. P Jajoria V Murthy E Papalardo, et al. 2009 Statins for the treatment of antiphospholipid syndrome? Ann NY Acad Sci 1173 736 45 19758223 10.1111/j.1749-6632.2009.04815.x 1:CAS:528:DC%2BD1MXhtlCnt73I This is a comprehensive review of statin use in APS
45. CC Belizna V Richard C Thuillez, et al. 2007 Insights into atherosclerosis therapy in antiphospholipid syndrome Autoimmun Rev 7 46 51 17967725 10.1016/j.autrev.2007.06.002 1:CAS:528:DC%2BD1cXitVWgtw%3D%3D (Pubitemid 47633391)